The development of OX19 is focused on more effective pharmaceutical forms of desmopressin in order to more effectively treat incontinence. In addition to the treatment of nocturia, the product is also being developed for the short-term, on-demand treatment of urinary incontinence in women suffering from an overactive bladder.
Market
Many elderly people suffer from nocturia and incontinence is especially common among women. The peptide drug desmopressin is considered to be the most effective drug for many of these patients.
Project status
Orexo has developed a nasal powder formulation for administering desmopressin. Data from a Phase I study confirm that this formulation offers significantly better uptake than nasal sprays currently on the market. The next step is to seek partnership for further development of the product.